US FDA Publishes Final Rule Amending Food Regulations for Use of SONOVA® GLA Safflower Oil in Dog Food
August 15 2017 - 8:00AM
Business Wire
-- Arcadia Biosciences Launches Sales of
SONOVA GLA Safflower Oil as a Healthy Ingredient and Rich Source of
Omega-6 Fatty Acids --
Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural
technology company, announced today that the U.S. Federal Register
has published the Food and Drug Administration’s (FDA) approval of
Arcadia’s food additive petition that its SONOVA® GLA safflower oil
is safe and nutritious for use in dog diets. This approval allows
Arcadia to launch sales of its SONOVA GLA safflower oil to pet
nutrition companies as a rich source of omega-6 fatty acids in
their dog food formulations.
Arcadia’s SONOVA gamma linolenic acid (GLA) safflower oil is a
highly-concentrated source of omega-6 fatty acids GLA and linoleic
acid (LA) and has been used in human nutritional supplements since
its approval by the FDA in 2009. Clinical studies have shown that
GLA offers similar benefits for pets, including weight management,
control of pruritus and other dermatological conditions,
mobility-related arthritic conditions and immune system disorders.
Arcadia’s SONOVA GLA safflower oil contains a minimum of 40 percent
GLA, which is approximately two to four times greater than most
other commercial sources, making it the most concentrated and
cost-effective plant oil source of GLA available.
“The Federal Register publication completes FDA’s approval of
SONOVA GLA safflower oil and, beginning today, opens up an entirely
new market for the sale of GLA in the fast-growing specialty market
of pet nutrition,” said Raj Ketkar, president and CEO of Arcadia
Biosciences. “GLA safflower oil is now the only approved source of
gamma linolenic acid for use in dog food in the U.S.”
Publication in the Federal Register completes the issuance of a
new food regulation: “Title 21, Code of Federal Regulations (21
CFR), part 573 – Food Additives Permitted in Feed and Drinking
Water of Animals – be amended to provide for the safe use of
gamma-linolenic acid (GLA) safflower oil as a source of omega-6
fatty acids in dry food for adult dogs.” FDA concluded that it had
completed its review and found that “the data adequately support
the safety and functionality of GLA safflower oil as a source of
omega-6 fatty acids in dry food for adult dogs.”
For more information on Arcadia’s SONOVA GLA for use in pet
food, visit: www.sonovaglapet.com.
About Arcadia Biosciences, Inc.
Based in Davis, Calif., Arcadia Biosciences (Nasdaq: RKDA)
develops agricultural products that create added value for farmers
while benefitting the environment and enhancing human health.
Arcadia’s agronomic performance traits, including Nitrogen Use
Efficiency, Water Use Efficiency, Salinity Tolerance, Heat
Tolerance and Herbicide Tolerance, are all aimed at making
agricultural production more economically efficient and
environmentally sound. Arcadia’s nutrition traits and products are
aimed at creating healthier ingredients and whole foods with lower
production costs. For more information, visit
www.arcadiabio.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the company’s GLA safflower
oil products and the regulatory process for such products.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially, and reported
results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not
limited to: the company’s and its partners’ and affiliates’ ability
to identify and isolate desired traits; the company’s and its
partners’ ability to develop commercial products incorporating GLA
safflower oil, and complete the regulatory review process for such
products; the company’s compliance with laws and regulations that
impact the company’s business, and changes to such laws and
regulations; the company’s future capital requirements and ability
to satisfy its capital needs; and the other risks set forth in the
company’s filings with the Securities and Exchange Commission from
time to time, including the risks set forth in the company’s Annual
Report on Form 10-K for the year ended December 31, 2016. These
forward-looking statements speak only as of the date hereof, and
Arcadia Biosciences, Inc. disclaims any obligation to update these
forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170815005412/en/
Arcadia Biosciences, Inc.Jeff
Bergaujeff.bergau@arcadiabio.com+1-312-217-0419
Arcadia Biosciences (NASDAQ:RKDA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arcadia Biosciences (NASDAQ:RKDA)
Historical Stock Chart
From Sep 2023 to Sep 2024